APLS insider trading
HealthcareApellis Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Company website: apellis.com
APLS insider activity at a glance
FilingIQ has scored 1,277 insider transactions for APLS since Nov 13, 2017. The most recent filing in our index is dated May 14, 2026.
Across the full history, 17 open-market purchases
and 450 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on APLS insider trades is 57.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest APLS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading APLS
13F funds holding APLS
Frequently asked
- How many insider trades does FilingIQ track for APLS?
- FilingIQ tracks 1,277 Form 4 insider transactions for APLS (Apellis Pharmaceuticals, Inc.), covering filings from Nov 13, 2017 onwards. 279 of those were filed in the last 90 days.
- Are APLS insiders net buyers or net sellers?
- Across the full Form 4 history for APLS, 17 transactions (1%) were open-market purchases and 450 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does APLS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is APLS in?
- Apellis Pharmaceuticals, Inc. (APLS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.75B.
Methodology & sources
Every APLS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.